Aarhus, Denmark

Meta-IQ develop medicine for the treatment of brain diseases like Alzheimer, Depression and Multiple Sclerosis by influencing the metabolism

Meta-IQ was founded February 2008 by Jette and John Nieland

Meta-IQ is a story of coincidence, innovative thinking, not giving up and your chance to be part of history and on the way gain something from it

Jette and John Nieland 2010 2

Jette G. K. Nieland, CEO, MSc in clinical and business psych. Responsible for financial and business development

John D. Nieland, COO, Assoc. prof. biotech., Ph.D. in medicine Responsible for research and organization of clinical trials

Jette and John Nieland 2010 3

Mogens Kloth-Malmqvist Business manager MK Invest & Consulting GmbH

Peter Heinrich Key advisor MagForce nanotechnologies AG

Martin Kloth Business controller MK Invest & Consulting GmbH

Jakob Krag Nielsen Contracts Plessner

Ulla Klinge Patent Inspicos A/S

Jens Fahlberg Certified tax advisor Rådgivning & Revision A/S

Ove Wiborg Research Aarhus University Hospital

Jette and John Nieland 2009 4

Your body is controlled by your brain which controls it by sending signals (energy package) through your body

There are 2 energy sources for cells, glucose and fatty acids

Different kind of stress makes the metabolism shift from a glucose to fatty acid metabolism

A cascade of processes is starting in the brain, which can lead to different brain diseases.

The balace between metabolism, immune system and CNS is challenged

Jette and John Nieland 2010 5

The only way to block all these processes effectively is by reversing the energy generation.

We treat the disease by blocking fatty acid metabolism

We reset the body functions and restore the balance in the system

We force the normal body functions to take care of the disease itself

We treat patients for weeks not for years

Jette and John Nieland 2010 6

Palmitate coupled to Myelin is the isolation around nerve cells

Jette and John Nieland 2010 7

Blocking fatty acid metabolism reverts the disease inducing cascade

Jette and John Nieland 2009 8

0

20

40

60

80

Long term memory

Short term memory

% a

nim

als w

ith

rest

ored

mem

ory

1 day treatment with MIQ 001 restores memory

PlaceboMIQ 001

Jette and John Nieland 2010 9

Rats are stressed for several week after which 50% get depressed. Then the depressed animal are

treated either with M-IQ 002 or placebo. As a control

normal animals are treated with either M-IQ 002 or

placebo.

Within 1 week up to 70 % and within 4 weeks 95% of

the animals respond.

Normal medicine on the market gives maximally 50% response rate after completion of treatment.

0

20

40

60

80

100

before treatment week 1 week 4

% N

orm

al A

nim

als

Normal Stressed M-IQ 002 Stressed Vehicle

Jette and John Nieland 2010 10

The responding animals show maximal

response within 1 week of treatment, in contrast medicine on

the market takes about 3-4 week before an effect starts being

visible.

Escitralopram data are from historic

experiments as comparison

Jette and John Nieland 2009 11

0102030405060

M-IQ 003 Placebo

% H

ealth

y An

imal

sMIQ 003 can cure mice with

Multiple Sclerosis

Depression (MIQ-002)Of the animals; 70% within 1 week and 95% after 4 weeks are curedMedicine on the market gives maximally 50% response rate in a 6 weeks treatment with the first effects visible after 3 - 4 weeks

Alzheimer (MIQ-001)A one day treatment with MIQ 001 restores;40% long term memory 60% short term memory

Multiple Sclerosis (MIQ-003)50% of the diseased animals are cured within 2 weeks of treatment

Jette and John Nieland 2010 12

Depression (MIQ-002)Depression is the most prevalent psychological diseaseover 10 % of the population suffer from itThe annual market is 12 billion USD

Alzheimer (MIQ-001)1% of people will get Alzheimer, and over 65 years it goes up to 5%The annual market is 5 billion USD

Multiple Sclerosis (MIQ-003)Worldwide about 2,5 million people suffer from multiple sclerosisfor which there is no treatment available The annual market is 5 billion USD

Jette and John Nieland 2010 13

The global rightsThe global rights have been in-licensed to these compounds for all disease indications

Manufacturing process establishedActive Pharmaceutical ingredient (API) is available at GMP-grade (Good Manufacturing Praxis)

Pre-clinical development ,Pharm/Toxic studies completedToxicity pharmacology package is complete to start human clinical phase 2 trials

Proof of concept reachedProof of concepts for Alzheimer and the treatment of Depression has been reached

We have filed patentsPatents cover the product for the treatment of brain and other diseases and will give protection until 2029

Due diligence of Meta-IQJune 2010 MedTech Innovation Center, Aarhus arranged due diligence of Meta-IQ with a very positive outcome

Jette and John Nieland 2010 14

Meta-IQ is looking for a 7 million € investment to start the clinical phase 2 trial in depression and a small phase I trial in Alzheimer

To go into phase 2 trials for Alzheimer or Multiple Sclerosis we need an additional 3 million € for each indication

Jette and John Nieland 2010 15

In the first year:Formulate medicine, get ethical and medical comity approval for clinical trial

In the second year:Run phase 2 clinical trial in Depression and after 6 months start a phase I clinical trial in Alzheimer

In the third year:Analyze the results of the depression study and out-license or sell project to big pharma company. Finish clinical trial in Alzheimer and start evaluating results

Jette and John Nieland 2010 16

1. Develop projects through phase 1 and 2 clinical trials2. Out-license or sell projects to Big Pharma3. Develop own projects 4. In-license projects

Jette and John Nieland 2010 17

To investors we offer the opportunity of being part of making new history in treating brain diseases

Promising financial perspectives in relation to the risks of the project

Because of the know how, CMC, preclinical and clinical data in Meta-IQ

The medicine can reach a leading position in major indications

For investors, a possibility of an exit after 3 years

Jette and John Nieland 2010 18

You can invest in this dynamic and innovative company and make profit

in 3 years

You or your family will be able to gain from its medicine in 8 years

Thank you for your attention